Coagulation factor concentrates: past, present, and future

[1]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[2]  J. Spira,et al.  Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. , 2006, Blood.

[3]  P. Lollar,et al.  Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII , 2006, Journal of thrombosis and haemostasis : JTH.

[4]  H. Metzner,et al.  Comparative Analysis and Classification of von Willebrand Factor/Factor VIII Concentrates: Impact on Treatment of Patients with von Willebrand Disease , 2006, Seminars in thrombosis and hemostasis.

[5]  P. Aurup,et al.  Off-Label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII , 2006, Journal of intensive care medicine.

[6]  M W Skinner,et al.  Treatment for all: a vision for the future , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  S. Pederson,et al.  Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. , 2006, Blood.

[8]  P. Mannucci,et al.  Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia , 2006, Journal of thrombosis and haemostasis : JTH.

[9]  P. Babyn,et al.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.

[10]  E. Santagostino,et al.  A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors , 2006, Journal of thrombosis and haemostasis : JTH.

[11]  H G Watson,et al.  Guidelines on oral anticoagulation (warfarin): third edition – 2005 update , 2006, British journal of haematology.

[12]  J. Weinberger.  Recombinant activated factor VII for acute intracerebral hemorrhage. , 2006, Current cardiology reports.

[13]  M. Diamond,et al.  Clinical perspectives of emerging pathogens in bleeding disorders , 2006, The Lancet.

[14]  M. Braun,et al.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.

[15]  G. Mariani,et al.  Congenital factor VII deficiency: therapy with recombinant activated factor VII – a critical appraisal , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  M. Turner,et al.  Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products , 2006, British journal of haematology.

[17]  Eric E. Smith,et al.  Timing of Fresh Frozen Plasma Administration and Rapid Correction of Coagulopathy in Warfarin-Related Intracerebral Hemorrhage , 2006, Stroke.

[18]  S. Opal,et al.  Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation , 2006, Journal of thrombosis and haemostasis : JTH.

[19]  L. Aledort,et al.  Therapeutic decision‐making in inhibitor patients , 2006, American journal of hematology.

[20]  R. Seitz,et al.  Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: In vitro and in vivo evidence , 2005, Thrombosis and Haemostasis.

[21]  J. Goudemand,et al.  United States' factor XI‐deficiency patients need a safer treatment , 2005, American journal of hematology.

[22]  L. Valentino,et al.  Initial Results of a Randomized, Prospective Trial of Prophylaxis To Prevent Joint Disease in Young Children with Factor VIII (FVIII) Deficiency. , 2005 .

[23]  J. Astermark,et al.  The FEIBA® NovoSeven® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors. , 2005 .

[24]  Jerome B. Zeldis,et al.  Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). , 2005 .

[25]  P. Giangrande,et al.  Variant Creutzfeldt–Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty , 2005, Vox sanguinis.

[26]  J. Ingerslev,et al.  Tailoring haemostatic treatment to patient requirements – an update on monitoring haemostatic response using thrombelastography , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  P. Mannucci,et al.  Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods , 2005, Journal of thrombosis and haemostasis : JTH.

[28]  N. Carlson,et al.  Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa. , 2005, The American journal of medicine.

[29]  J. García-Valdecasas,et al.  Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[30]  S. Pipe.  The promise and challenges of bioengineered recombinant clotting factors , 2005, Journal of thrombosis and haemostasis : JTH.

[31]  M. Spannagl,et al.  Hochdosierte Fibrinogengabe zur Akuttherapie von Gerinnungsstörungen bei perioperativer Massivtransfusion , 2005, Der Anaesthesist.

[32]  G. Klintmalm,et al.  Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  D. Kajdasz,et al.  Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. , 2005, The Journal of thoracic and cardiovascular surgery.

[34]  R. Rossaint,et al.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. , 2005, The Journal of trauma.

[35]  W. Kreuz,et al.  Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[36]  R. Grounds,et al.  Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. , 2005, British journal of anaesthesia.

[37]  M. Kamien.  Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis , 2005, The Medical journal of Australia.

[38]  P. Marks,et al.  Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[39]  W. Bechstein,et al.  Recombinant Coagulation Factor VIIa in Major Liver Resection: A Randomized, Placebo-controlled, Double-blind Clinical Trial , 2005, Anesthesiology.

[40]  V. Blanchette,et al.  The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. , 2005, Blood.

[41]  C. Rothschild,et al.  Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A , 2005, Thrombosis and Haemostasis.

[42]  Dougald M Monroe,et al.  The use of recombinant factor VIIa in the treatment of bleeding disorders. , 2004, Blood.

[43]  N. Key.  Inhibitors in congenital coagulation disorders , 2004, British journal of haematology.

[44]  S. Greenberg,et al.  Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage , 2004, Neurology.

[45]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[46]  R. Seitz,et al.  Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[47]  J. Duguid,et al.  Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant , 2004, British journal of haematology.

[48]  G. Kenet,et al.  Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors , 2004, Journal of thrombosis and haemostasis : JTH.

[49]  W. V. van Heerde,et al.  Prophylactic effect of recombinant factor VIIa in factor VII deficient patients , 2004, British journal of haematology.

[50]  P. Mannucci,et al.  Human recombinant DNA‐derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation , 2004, Journal of thrombosis and haemostasis : JTH.

[51]  G. Rivard,et al.  Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[52]  J. Gill,et al.  Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate‐P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[53]  John Wu,et al.  Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia , 2003, Thrombosis and Haemostasis.

[54]  K. Fischer,et al.  Prophylaxis for severe haemophilia: clinical and economical issues , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[55]  R. Peters,et al.  Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers , 2003 .

[56]  J. Astermark,et al.  Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay , 2003, Pathophysiology of Haemostasis and Thrombosis.

[57]  K. Pasi,et al.  Haemophilias A and B , 2003, The Lancet.

[58]  B. Konkle,et al.  Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures , 2003, Transfusion.

[59]  K. Kurth,et al.  Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial , 2003, The Lancet.

[60]  R. Lorenz,et al.  Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage , 2003, European journal of gastroenterology & hepatology.

[61]  C. Kessler,et al.  Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.

[62]  R. Peters,et al.  Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers , 2002, Circulation.

[63]  J. Löwer,et al.  Parvovirus B19 transmission by heat‐treated clotting factor concentrates , 2002, Transfusion.

[64]  E. Deconinck,et al.  Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases , 2002, Transplantation.

[65]  D. Perry.  Factor VII Deficiency. , 2002, British journal of haematology.

[66]  W. Erber.  Massive blood transfusion in the elective surgical setting. , 2002, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[67]  H. Ehrlich,et al.  Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[68]  S. Kitchen,et al.  Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients , 2002, British journal of haematology.

[69]  P. Mannucci,et al.  Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. , 2002, Blood.

[70]  T. Baglin,et al.  Beriplex P/N reverses severe warfarin‐induced overanticoagulation immediately and completely in patients presenting with major bleeding , 2001, British journal of haematology.

[71]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[72]  M. Kiehl,et al.  Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience. , 2001, Transplantation.

[73]  P. Mannucci.  How I treat patients with von Willebrand disease. , 2001, Blood.

[74]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[75]  S. Pescatore,et al.  Clinical management of protein C deficiency , 2001, Expert opinion on pharmacotherapy.

[76]  K. Lewis,et al.  Factor XIIIA and clot strength after cardiopulmonary bypass , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[77]  J. Di Paola,et al.  Current therapy for rare factor deficiencies , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[78]  R. Parameswaran,et al.  Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[79]  G. Mariani,et al.  Clinical manifestations, management, and molecular genetics in congenital factor VII deficiency: the International Registry on Congenital Factor VII Deficiency (IRF7) , 2000, Blood.

[80]  H. Schwarz,et al.  Factor Xa and Prothrombin: Mechanism of Action of FEIBA , 1999, Vox Sanguinis.

[81]  M. Köhler.  Thrombogenicity of prothrombin complex concentrates. , 1999, Thrombosis research.

[82]  P. Zapater,et al.  Long-term Management of Homozygous Protein C Deficiency: Replacement Therapy with Subcutaneous Purified Protein C Concentrate , 1999, Thrombosis and Haemostasis.

[83]  H. Fiedler.  Factor VII and Activated Factor VII Content of Prothrombin Complex Concentrates , 1998, Vox sanguinis.

[84]  B. Schmidt,et al.  A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. , 1998, American journal of respiratory and critical care medicine.

[85]  J. Oliver,et al.  A possible mechanism of action of activated factor VII independent of tissue factor. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[86]  J. Goedert,et al.  Estimating the cumulative incidence of HIV infection among persons with haemophilia in the United States of America. , 1998, Statistics in medicine.

[87]  P. Hellstern,et al.  Factor VII and Activated‐ Factor‐VII Content of Prothrombin Complex Concentrates 1 , 1997, Vox sanguinis.

[88]  C. Rothschild,et al.  Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors , 1997, Thrombosis and Haemostasis.

[89]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[90]  Vittorio Pengo,et al.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.

[91]  G. Rivard,et al.  Treatment of purpura fulminans in meningococcemia with protein C concentrate. , 1995, The Journal of pediatrics.

[92]  P. Kyrle,et al.  Antithrombin III Concentrates-Are they Clinically Useful? , 1995, Thrombosis and Haemostasis.

[93]  M. Karck,et al.  Heart transplantation under coumarin therapy: friend or foe? , 1994, European journal of anaesthesiology.

[94]  P. Mannucci,et al.  Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery , 1994, Thrombosis and Haemostasis.

[95]  E. Gordon,et al.  A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.

[96]  S. Arkin,et al.  Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors , 1993 .

[97]  F. Rosendaal,et al.  A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. , 1993, Blood.

[98]  E. MAUSER‐BUNSCHOTEN,et al.  HIV infection in haemophilia--a European cohort. , 1993, Archives of disease in childhood.

[99]  S. Arkin,et al.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.

[100]  L. J. Logan,et al.  Treatment of von Willebrand's disease. , 1992, Hematology/oncology clinics of North America.

[101]  L. Winkelman,et al.  Production and Therapeutic Use of a Factor XI Concentrate from Plasma , 1992, Thrombosis and Haemostasis.

[102]  J. Magny,et al.  Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. , 1991, The New England journal of medicine.

[103]  M. Makris,et al.  Potential thrombogenicity of heat‐treated prothrombin complex concentrates in Haemophilia B , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[104]  M. Hilgartner,et al.  Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study Group , 1990, Transfusion.

[105]  M. Houghton,et al.  Hepatitis C antibody and chronic liver disease in haemophilia , 1990, The Lancet.

[106]  J. Goedert,et al.  A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. , 1989, The New England journal of medicine.

[107]  A. McCraw,et al.  Inheritance and bleeding in factor XI deficiency , 1988, British journal of haematology.

[108]  E. Chen,et al.  Characterization of the human factor VIII gene , 1984, Nature.

[109]  G. Knutson,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor , 1984, Nature.

[110]  D. Rees,et al.  The gene structure of human anti‐haemophilic factor IX. , 1984, The EMBO journal.

[111]  Lusher Jm.  Myocardial necrosis after therapy with prothrombin-complex concentrate. , 1984 .

[112]  P. Levine,et al.  Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. , 1983, Blood.

[113]  R. Aster,et al.  Generalized lymphadenopathy and T cell abnormalities in hemophilia A. , 1983, The Journal of pediatrics.

[114]  H. V. van Houwelingen,et al.  The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. , 1981, The New England journal of medicine.

[115]  P. Mannucci,et al.  CORRECTION OF ABNORMAL COAGULATION IN CHRONIC LIVER DISEASE BY COMBINED USE OF FRESH-FROZEN PLASMA AND PROTHROMBIN COMPLEX CONCENTRATES , 1976, The Lancet.

[116]  M. Colombo,et al.  Asymptomatic liver disease in haemophiliacs. , 1975, Journal of clinical pathology.

[117]  H. Kingdon,et al.  Thrombogenic materials in prothrombin complex concentrates. , 1974, Annals of internal medicine.

[118]  T. Barrowcliffe,et al.  Small Scale Preparation and Clinical Use of Factor IX‐Prothrombin Complex , 1973, Vox sanguinis.

[119]  C. Kasper,et al.  Hepatitis and clotting-factor concentrates. , 1972, JAMA.

[120]  P. Bruning,et al.  Prothrombal: A New Concentrate of Human Prothrombin Complex for Clinical Use , 1971, British journal of haematology.

[121]  H. Roberts,et al.  A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. , 1968, JAMA.

[122]  H. Roberts,et al.  CLINICAL USE OF A NEW GLYCINE‐PRECIPITATED ANTIHEMOPHILIC FRACTION , 1965, The American journal of the medical sciences.

[123]  Harrison Rg.  Blood-supply of the testis. , 1948 .

[124]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. ONTARGET Renal Outcomes TRANSCEND , 2008 .

[125]  D. Angus.  Caring for the Critically Ill Patient , 2007 .

[126]  J. Spira,et al.  Prolonged Bleeding-free Period Following Prophylactic Infusion of Recombinant Factor VIII (Kogenate FS) Reconstituted with Pegylated Liposomes , 2006 .

[127]  D. Nugent.  Prophylaxis in rare coagulation disorders -- factor XIII deficiency. , 2006, Thrombosis research.

[128]  J. Hemphill,et al.  Treating warfarin-related intracerebral hemorrhage: is fresh frozen plasma enough? , 2006, Stroke.

[129]  T. Lambert,et al.  Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. , 2006, Blood.

[130]  H. Naritomi,et al.  Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. , 2005, Thrombosis research.

[131]  M. Spannagl,et al.  [High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion]. , 2005, Der Anaesthesist.

[132]  M. Siddiqui,et al.  Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. , 2005, Drugs.

[133]  M. O’Donnell,et al.  New anticoagulants. , 2005, Blood.

[134]  Jay Steingrub,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005 .

[135]  G. Nelsestuen,et al.  Views on methods for monitoring recombinant factor VIIa in inhibitor patients. , 2004, Seminars in hematology.

[136]  C. Dubois,et al.  Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2 , 2004 .

[137]  J. Helterbrand,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .

[138]  S. Opal,et al.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. , 2001, JAMA.

[139]  J. Arnout,et al.  Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate , 1997, Thrombosis and Haemostasis.

[140]  P. Olbert,et al.  Factor XIII in Chronic Inflammatory Bowel Diseases , 1996, Seminars in thrombosis and hemostasis.

[141]  D. Rees,et al.  Molecular cloning of the gene for human anti-haemophilic factor IX , 1982, Nature.

[142]  S. Shapiro,et al.  Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial. , 1980, Transactions of the Association of American Physicians.